On November 8, 2023, Forward Therapeutics, a biopharmaceutical company developing small molecule therapies for chronic immunological and inflammatory disorders, announced that it raised $50 million in Series A funding. Wilson Sonsini Goodrich & Rosati advised Forward Therapeutics on IP matters related to the transaction.

The round was led by BVF Partners with participation from other life sciences investors RA Capital Management and OrbiMed. Forward Therapeutics has partnered with Curie.Bio, a new model for venture capital in biotech focused on helping founders launch therapeutics companies.

The company intends to use the funds to advance its portfolio of novel, small molecule immunology medicines towards clinical development.

Under the leadership of Toufike Kanouni, chief executive officer, and Ewan Taylor, chief scientific officer, Forward Therapeutics is dedicated to advancing the treatment of chronic inflammatory disorders via a pipeline of novel, next-generation small molecule immune therapies.

The Wilson Sonsini team that advised Forward Therapeutics on IP matters and provided general guidance on patent-related issues included David Clark, Deborah Smith, and Michael Hostetler.

For more information, please refer to the press release from Forward Therapeutics. Additional coverage can be found on Endpoints News and STAT News.